The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study (CPLCC)

Genetic Susceptibility Study of Primary Pulmonary Lymphoepithelioma-like Carcinoma

This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.

Study Overview

• Status: Recruiting
• Conditions: Primary Pulmonary Lymphoepithelioma-like Carcinoma
• Intervention / Treatment: Genetic: Genome-wide genotyping

Detailed Description

Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) that histologically resembles nasopharyngeal carcinoma (NPC) and predominantly affects the Asian population. Epstein-Barr virus (EBV) infection is a recognized pathogenic factor, and the regional prevalence of pLELC suggests that genetic susceptibility also plays an important role. However, no genetic studies on pLELC have been conducted, leaving its genetic etiology poorly understood. In this study, genotyping for all the subjects was performed by using Illumina Infinium Global Screening Array. Genome-wide association followed by meta-analysis was performed for pLELC cases and healthy controls. The primary objective of this study is to discover susceptibility genes that explain the genetic mechanisms of pLELC.

• Study Type: Observational
• Enrollment (Estimated): 10000

Contacts and Locations

• Study Contact: Name: Wei-Hua Jia, MD; Phone Number: 86+020-87342327; Email: jiawh@sysucc.org.cn
• Study Contact Backup: Name: Tong-Min Wang, PhD; Phone Number: 86+020-87342410; Email: wangtm@sysucc.org.cn

Study Locations

• China
  • Guangdong
    • Foshan, Guangdong, China, 528000
      • Recruiting
      • Foshan First People's Hospital
      • Contact: Liu Fang; Phone Number: 86+18038860223; Email: gyliuf@126.com
    • Guangzhou, Guangdong, China, 510060
      • Recruiting
      • Sun yat-sen University Cancer Center
      • Contact: Jia Wei-Hua; Phone Number: 86+020-87342327; Email: jiawh@sysucc.org.cn
      • Contact: He Yong-Qiao; Phone Number: 86+020-87342410; Email: heyq@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

The study population consisted of cases and controls with specific inclusion and exclusion criteria. Cases were individuals pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma (PLELC), excluding those with metastatic nasopharyngeal carcinoma or severe cardiovascular, liver, or kidney disease. Controls were individuals in good physical condition with stable levels of consciousness, excluding those with a history of cancer or severe cardiovascular, liver, or kidney disease.

Description

Case:

Inclusion criteria:

The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma.

Exclusion criteria:

The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease.

Controls:

Inclusion criteria:

The subject is in good physical condition and has a stable level of consciousness;

Exclusion criteria:

The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
SYSUCC cohort, Guangdong, China; Cases: Patients aged 18 and above with a pathological diagnosis of primary pulmonary lymphoepithelioma-like carcinoma who were treated at the Sun Yat-sen University Cancer Center from January 1, 2002. Controls: Healthy participants aged 18 and above.	Genetic: Genome-wide genotyping; Whole blood from the participants was used to extract DNA for genotyping.
Foshan cohort, Guangdong, China; Cases: Patients aged 18 and above with a pathological diagnosis of primary pulmonary lymphoepithelioma-like carcinoma who were treated at the the First People's Hospital of Foshan from January 1, 2007. Controls: Healthy participants aged 18 and above.	Genetic: Genome-wide genotyping; Whole blood from the participants was used to extract DNA for genotyping.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the occurrence of Pulmonary Lymphoepithelioma-like Carcinoma	pathological diagnosis of Pulmonary Lymphoepithelioma-like Carcinoma	The enrollment of the participants

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Collaborators: First People's Hospital of Foshan

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2002
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: January 24, 2025
• First Submitted That Met QC Criteria: January 24, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 24, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Genome-Wide Association Study; primary Pulmonary Lymphoepithelioma-like Carcinoma
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Carcinoma
• Other Study ID Numbers: SL-B2025-059-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: To prioritize participant confidentiality and privacy, we have decided not to release Individual Participant Data (IPD). This decision reflects our commitment to safeguarding the sensitive information of participants, in full compliance with ethical standards and privacy laws. It is taken to protect the well-being and privacy of all individuals involved in the study.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No